Nandita Shangari
Directeur/Membre du Conseil chez Capstan Therapeutics, Inc.
Profil
Nandita Shangari is currently a Director at Mediar Therapeutics, Inc. and a Director at Renovacor Holdings, Inc., Capstan Therapeutics, Inc., and Principal at Novartis Venture Funds (USA).
She was previously an Independent Director at TScan Therapeutics, Inc.
Postes actifs de Nandita Shangari
Sociétés | Poste | Début |
---|---|---|
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | Private Equity Investor | - |
Renovacor Holdings, Inc.
Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | Directeur/Membre du Conseil | - |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company that develops targeted in vivo RNA technologies to multiply therapeutic possibilities for patients. Capstan Therapeutics is based in San Diego, CA. The company's platform technology, tLNPs, delivers payloads capable of reprogramming specific cell types in vivo, including gene editing tools. The company aims to generate transformative therapies for autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. The company was founded in 2022 by Haig Aghajanian, and the CEO is Laura K. Shawver. | Directeur/Membre du Conseil | - |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | 15/03/2023 |
Anciens postes connus de Nandita Shangari
Sociétés | Poste | Fin |
---|---|---|
TSCAN THERAPEUTICS, INC. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
TSCAN THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | Finance |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | Health Technology |
Renovacor Holdings, Inc.
Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | Health Technology |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company that develops targeted in vivo RNA technologies to multiply therapeutic possibilities for patients. Capstan Therapeutics is based in San Diego, CA. The company's platform technology, tLNPs, delivers payloads capable of reprogramming specific cell types in vivo, including gene editing tools. The company aims to generate transformative therapies for autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. The company was founded in 2022 by Haig Aghajanian, and the CEO is Laura K. Shawver. | Commercial Services |